At the beginning of his tenure, now-outgoing US FDA Commissioner Scott Gottlieb said the agency will be prioritizing the development of disease-specific guidance documents as a way to facilitate innovative drug development. (Also see "FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development" - Pink Sheet, 12 September, 2017.) He certainly looks to have kept that promise.
A Pink Sheet analysis of FDA guidance documents shows that FDA issued 36 disease-specific guidances during Gottlieb's nearly 22 months...







